Cargando…

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC) worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC treated with Nivolumab is still under debate. This meta-analysis was to assess the significance of NLR as a predictive factor in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Dedong, Xu, Huilin, Xu, Ximing, Guo, Tao, Ge, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205035/ https://www.ncbi.nlm.nih.gov/pubmed/30377569 http://dx.doi.org/10.1080/2162402X.2018.1507262

Ejemplares similares

The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: dedong, Cao, et al.
Publicado: (2016)

The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials
por: Ge, Wei, et al.
Publicado: (2018)

Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2023)

Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis
por: Cao, Dedong, et al.
Publicado: (2019)

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
por: Xu, Huilin, et al.
Publicado: (2020)

The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis
por: Zhao, Nan, et al.
Publicado: (2022)

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
por: Liu, Xiaohong, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Insulin promotes progression of colon cancer by upregulation of ACAT1
por: Chen, Xin, et al.
Publicado: (2018)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

The Impact of Javanica Oil Emulsion Injection on Chemotherapy Efficacy and Cellular Immune Indicators in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2019)

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
por: Ogimoto, Tatsuya, et al.
Publicado: (2023)

Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2023)

Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Xu, Huilin, et al.
Publicado: (2023)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

System identification: a feasible, reliable and valid way to quantify upper limb motor impairments
por: van de Ruit, Mark, et al.
Publicado: (2023)

The extracellular vesicles secreted by lung cancer cells in radiation therapy promote endothelial cell angiogenesis by transferring miR-23a
por: Zheng, Yongfa, et al.
Publicado: (2017)

The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials
por: Zhao, Binghao, et al.
Publicado: (2018)

Nivolumab‐induced sialadenitis
por: Takahashi, Saeko, et al.
Publicado: (2018)

The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review
por: Tong, Hongxuan, et al.
Publicado: (2020)

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
por: Weber, Jeffrey, et al.
Publicado: (2015)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study
por: Zhai, Hengyu, et al.
Publicado: (2022)

Evaluating the potential benefits of the extravascular pool of factor IX
por: Lillicrap, David
Publicado: (2021)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

Nivolumab: Cutaneous small-vessel thrombotic vasculopathy: case report
Publicado: (2022)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
por: Ikoma, Tatsuki, et al.
Publicado: (2022)

Reliable multiplex generation of pooled induced pluripotent stem cells
por: Smullen, Molly, et al.
Publicado: (2023)

Feasibility of pooling annotated corpora for clinical concept extraction
por: Wagholikar, Kavishwar, et al.
Publicado: (2012)

The site reliability workbook: practical ways to implement SRE
por: Beyer, Betsy
Publicado: (2018)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Feasibility, efficiency & effectiveness of pooled sample testing strategy (pooled NAAT) for molecular testing of COVID-19
por: Prakash, Shantanu, et al.
Publicado: (2021)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
por: Skeate, Joseph G., et al.
Publicado: (2020)

Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
por: Chen, Xin, et al.
Publicado: (2019)

JMP 14 reliability and survival methods
por: SAS Institute
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hj4bps74trupep8a52pejr4dts